简介：客观：借助于高分辨率图象分析(HRIA)预言食道的上皮的发育异常的结果。方法：无征状的成年人从Linxian县的Heshun公社在1983为食管的汽球细胞学被检查。93严重发育异常和食管的122温和发育异常被选择。借助于与电视照相机装备的一台Axiomat显微镜，在染色奶头的有鳞的上皮的中间的层的保存得很好的房间的100个正常原子核随机被检验。结果：93个cytologically诊断的严重发育异常盒子，24,14和7分别地在3，5和9年里进行了到癌。在另外的48个盒子中，发育异常仍然是马厩或regressed到正常。另外的盒子被用作控制。根据染色质特征，盒子的正确诊断被HRIA在75.0%完成(18/24)，85.7%(12/14)并且(6/7)85.7%盒子检验了，分别地(P<0.001)。122cytologically诊断的温和发育异常，16,13和12个盒子分别地在3，5和9年里进行了到癌。另外的81个盒子仍然是马厩或regressed到正常。正确诊断被HRIA在93.8%做(15/16)，76.9%(10/13)并且(10/12)833%盒子检验了，分别地(P<0.001)。结论：HRIA检验的染色质原子特征能预言癌症前期的损害的结果并且从non-progressor区别progressor。它能为chemo预防试用的效率的评估被用作代理人端点biomarkers。

简介：得到中央neurocytoma的更好的识别并且减少的目的错误诊断。回顾的评论识别了中央neurocytoma的15个盒子的方法。中央neurocytoma的所有情况为他们的临床的症状，病理学的变化，染色的immunohistochemical，预后和微分诊断被分析。临床列在后面在上面被执行。在那里的结果1064年是8男性和7女性(中部32.93年)。最普通的介绍症状是与增加的intracranial压力(ICP)有关的那些，包括头疼(100%)，papilledema(93%)并且呕吐(80%)。所有肿瘤位于室的系统。肿瘤由一致房间组成与围着原子核和一个好染色质模式，并且在一些区域，有perinuclear光圈的小房间能被看见。特别地，无核的区域可以有一个好fibrillary矩阵(neuropil)。原子atypia和脉管的增长分别地出现在二种情况中。焦点的坏死能在一种情况中被看见。Immunohistochemical调查结果包括了synaptophysin(15/15)的表示，神经原特定的enolase(12/15)和glialfibrillary酸的蛋白质(GFAP)(3/15)。MIB-1增长索引从0.812.5%，并且在估计的15个盒子中的3个中是超过2%。11个病人的后续信息是可得到的。结论中央neurocytoma一般来说，但是在里面有有利预后一些情况，临床的功课能是好攻击的。GFAP确实，增长索引和脉管的增长的增加可能建议一个更恶意的过程。

简介：OBJECT:Optimummanagementforelderlypatientswithnewlydiagnosedglioblastoma(GBM)inthetemozolomide(TMZ)eraisnotwelldefined.Theobjectofthisstudywastoclarifyoutcomesinthispopulation.METHODS:Theauthorsretrospectivelyreviewed105consecutivecasesinvolvingelderlypatients(age≥65years)withnewlydiagnosedGBMwhoweretreatedattheMayoClinicbetween2003and2008.RESULTS:Thepatients'medianagewas74years(range66-87years),andthemedianKarnofskyPerformanceStatus(KPS)scorewas80(range40-90).Halfofthepatientsunderwentbiopsyandhalfunderwentresection.Patientswithdeep-seatedlesions(19patients[18%])ormultifocallesions(34patients[32%])weremorelikelytohavebiopsythanresection(p=0.0001and0.0009,respectively).Newpersistentneurologicaldeficitsdevelopedin7patients(6.7%).Postoperativehemorrhageoccurredin6patients(5.7%),allofwhomunderwentbiopsy.Completefollow-updataregardingadjuvanttreatmentwasavailablein84patients.Forty-one(49%)weretreatedwithchemotherapy(mostlyTMZ)andradiationtherapy(RT),and23(27%)withRTalone.Nineteen(23%)receivedonlypalliativecareaftersurgery(morecommonwithbiopsy,p=0.03).Chemotherapycomplicationsoccurredin28.6%(Grade3or4hematologicalcomplicationsin11.9%).Themedianvaluesforprogression-freesurvival(PFS)andoverallsurvival(OS)were3.5and5.5months.Inamultivariateanalysis,youngerage(p=0.03,riskratio[RR]0.34,95%CI0.13-0.89),singlelesion(p=0.02,RR0.51,95%CI0.30-0.89),resection(p=0.04,RR0.54,95%CI0.31-0.94),andadjuvanttreatment(p=0.0001,RR0.24,95%CI0.11-0.49)wereassociatedwithbetterOS.OnlyadjuvanttreatmentwassignificantlyassociatedwithprolongedPFS(p=0.0007,RR0.27,95%CI0.13-0.57).Withcombinedtherapywithresection,RT,andchemotherapy,themedianPFSandOSwere8and12.5months,respectively.CONCLUSIONS:TheprognosisforGBMworsenswithincreasingageinelderlypatients.Withimportantrisks,resectionandadjuvanttreatmen

简介：Objective:Mucoepidermoidcarcinoma(MEC)isthemostcommonprimarymalignancyofthesalivaryglands.Insulin-likegrowthfactor-IImRNA-bindingprotein-3(IMP3)isanimportantprognosticfactorinsomecancersandatoolthatdifferentiatesbetweenbenignandmalignantpancreaticlesions.ThisstudyaimedtoidentifyarelationshipbetweentheexpressionofIMP3andtheoutcomeofsalivaryglandMEC,aswellastodifferentiateMECfrompleomorphicadenoma(PA).Methods:Tissuespecimensfrom70casesofsalivaryglandMEC,40casesofPA,and10caseswithnormalsalivaryglandwereexaminedimmunohistochemicallyforIMP3.TheassociationamongtheexpressionofIMP3,clinicopathologicalcharacteristicsandpatient'ssurvivalwasassessed.Results:IMP3waspresentin51.4%ofMECbutabsentinPAandnormalsalivaryglandtissues.IMP3expressionwasassociatedwithage>60years,submandibularglandtumors,tumorsize>4cm,high-gradetumors,lymphnodemetastasis,involvementofsurgicalmargins,perineuralinvasion,distantmetastasis,advancedTNMstage,tumorrelapse,anddeath(P<0.05).IncreasedexpressionofIMP3,tumorsofthesubmandibulargland,andlymphnodemetastasiswereindependentprognosticfactorsofdisease-freesurvival(DFS).Inaddition,IMP3wasastrongpredictorofoverallsurvival(OS)togetherwithdistantmetastasisandintermediateandhigh-gradetumors.Conclusions:IMP3expressionishighlyimportantinevaluatingtheoutcomeofMEC.IMP3canbeusedtodifferentiateMECfromPAofsalivaryglands.

简介：Purpose:Wntpathwayscontrolkeybiologicalprocessesthatpotentiallyimpactontumorprogressionandpatientsurvival.Thepresentstudyanalyzedthepolymorphismoflipoprotein-relatedreceptor5(LRP5)(genewithkeyfunctionsinWntsignaling)anditsimpactontheresponsetochemotherapyandsurvivalofpatientswithadvancedgastriccancer(AGC).Methods:Atotalof107consecutivepatientswithAGCtreatedwithfirst-linechemotherapyofEOFregimenwereenrolledinthepresentretrospectivestudy.Theassociationbetweensinglenucleotidepolymorphism(SNP)ofrs3736228inLRP5andtheclinicaloutcomesofthepatientswasstudied.Results:TheCCgenotypeofrs3736228wassignificantlycorrelatedwithahigherdiseasecontrolratewhencomparedtotheCTandTTgenotypes(89.3%and61.8%,respectively,P<0.001).Aunivariatesurvivalanalysisalsoshowedthattheprogressionfreesurvival(PFS)andoverallsurvival(OS)forthepatientswiththeTCandTTgenotypesofrs3736228wereworsethanforthepatientswiththeCCgenotype(PFS:3.3and6.7months,respectively,HR=0.454,P<0.001;OS:8.1monthsand18.8months,respectively,HR=3.056,P<0.001).AmultivariateCoxmodelincorporatesrs3736228andclinicalfeatures,alsoidentifiedrs3736228wassignificantlyassociatedwiththePFSandOS.Conclusions:OurresultsfirstlyhighlighttheimportanceofLRP5geneofWntpathwayinthetreatmentofAGCandidentifypolymorphismofrs3736228asindependentpredictorofdiseasecontrolrate,PFSandOSinAGCpatientstreatedwithfirst-linechemotherapyofEOFregimenintheChineseHanpopulation.

简介：先于尖锐myeloid白血病(AML)的Myeloid肉瘤(MS)是稀罕的，作为尖锐针的绳索压缩介绍是它甚至稀罕。这里，我们报导myeloid肉瘤病人，其结果不同的二个新案例。有针的MS前面的AML的27个病人迄今为止被报导了，包括在这篇文章介绍的二个案例。外科的解压缩在27个病人中的25个被执行，并且这些中的23个收到了另外的anti-AML治疗。就我们在文学的病人和出版案例而言，我们建议immunohistochemical学习在到达MS，和那个紧急情况手术的正确诊断到针的MS是的将切除起一个必要作用做神经功能恢复的可得到的治疗，并且疾病必须与类似于过去常在肿瘤的切除术或照耀以后尽快对待AML那的集中的化疗被治疗。

简介：

简介：Objective:Survivalbenefitofadjuvantchemotherapy(AC)ofpatientswithintrapulmonarylymphnode(IPLN)metastasis(level12-14)needsinvestigation.WeevaluatedtheimpactofAConpatientswhosemetastaticnodeswerelimitedtointrapulmonarylevelsaftersystematicdissectionofN1nodes.Methods:First,155consectivecasesoflungcancerconfirmedaspathologicN1werecollectedandevaluated.PatientsreceivedsystematicdissectionofN2andN1nodes.ForpatientswithIPLNmetastasis,survivaloutcomeswerecomparedbetweenthosereceivingACandthosenotreceivingAC.Results:Inthisgroup,112cases(72.3%)hadIPLNmetastasisand55cases(35.5%)hadN1involvementlimitedtolevel13-14withoutfurtherdiseasespreadtohigherlevels.PatientswithIPLNinvolvementhadabetterprognosisthanthatofpatientswithhilar-interlobarinvolvement.FortheintrapulmonaryN1group(level12-14-positive,level10-11-negativeorunknown,n=112),nosurvivalbenefitwasfoundbetweentheACgroupandnonACgroup[5-yearoverallsurvival(OS):54.6±1.6vs.50.4±2.4months,P=0.177].However,76of112casesforwhomharvestingoflevel-10andlevel-11nodeswasdonedidnotshowcancerinvolvementinpathologyreports(level12-14-positive,level10-11bothnegative),oncologicoutcomewasbetterforpatientsreceivingACthanthosenotreceivingACinthissubgroup(5-yearOS:57.3±1.5vs.47.1±3.2months,P=0.002).Conclusions:OncologicoutcomemaybeimprovedbyACforpatientswithinvolvementofN1nodeslimitedtointrapulmonarylevelsaftercompleteexaminationofN1nodes.

简介：

简介：Objective:Weinvestigatedthecorrelationbetweenthenumberofcirculatingtumorcells(CTCs)andwholebodymetabolictumorvolume(WBMTV)measuredby18F-fluorodeoxyglucose(FDG)positronemissiontomography/computedtomography(PET/CT).TheaimwastoevaluatethevalueoftheincorporationofCTCnumberandWBMTVintheprognosticpredictionofstageIIIsmall-celllungcancer(SCLC).Methods:Onehundredandtwenty-ninepatientswereenrolledinthisstudy.Allpatientsweretreatedwithfourcyclesofaplatinum-basedregimenandconcurrentchestirradiation,followedbyprophylacticcranialirradiation.BloodsamplesforCTCanalysiswereobtainedfrom112patientsbeforetheinitiationofchemotherapy(asabaseline),aftercycle1andaftercycle4.CTCsweremeasuredusingtheCELLSEARCH?system.ThepatientsunderwentpretreatmentFDGPET/CTWBMTV,whichincludedallmalignantlesions.TheSpearmanranktestwasusedtodeterminethecorrelationamongCTCcounts,WBMTVanddiseasestage.Overallsurvival(OS)andprogression-freesurvival(PFS)curveswereproducedusingtheKaplan-Meiermethod,andsurvivaldifferencesbetweengroupswereassessedbythelog-ranktest.Results:ThenumberofCTCsatbaselinedidnotcorrelatewithWBMTVbeforetheinitiationoftherapy(P=0.241).ThenumberofCTCsatbaselineandtheWBMTVbeforetheinitiationoftherapywereindependentrelevantfactorsforPFSandOS.Thesubgroupanalysis(GroupA:CTCcount>19.5andaWBMTV>266.5cm^3;GroupB:CTCcount>19.5andaWBMTV≤266.5cm^3;GroupC:CTCcount≤19.5andaWBMTV>266.5cm^3;GroupD:CTCcount≤19.5andaWBMTV≤266.5cm^3)showedthatthedifferenceswerestatisticallysignificantinthemedianPFS(GroupAvs.D,P<0.001;GroupBvs.D,P=0.018;GroupCvs.D,P=0.029)andinthemedianOS(GroupAvs.D,P<0.001;GroupBvs.D,P=0.012).Conclusions:CTCnumberandWBMTVarerelatedtoprogressionanddeathinpatientswithSCLC.TheincorporationofCTCnumberandWBMTVscanscanprovideadetailedprognosticpredictionforSCLC.

简介：Objective:Apreviousstudydemonstratedthatnon-anthracycline-containingdocetaxelpluscyclophosphamide(TC)regimenwasinferiortodocetaxel,anthracyclineandcyclophosphamide(TAC)inneoadjuvanttreatmentoftriple-negativebreastcancer(TNBC)andhumanepidermalgrowthfactorreceptor-2-(HER2)-positivebreastcancerinashort-termfollow-up.Herein,long-termfollow-upsurvivaloutcomeshavebeeninvestigated.Methods:TNBCorHER2-positivepatientswererandomizedtoreceive6cyclesofTCorTACneoadjuvanttreatment.Theprimaryendpointwaspathologicalcompleteremission(pCR).Secondaryendpointsincludedclinicalresponserate,event-freesurvival(EFS),andoverallsurvival(OS).Results:Acohortof96patientsconsistedof45inTCand51inTACarm.Withamedianfollow-upperiodof53(range,8–76)months,thepatientsachievingpCRpostneoadjuvantchemotherapyexhibitedsuperiorEFSandOSthanpatientswithoutpCR(P<0.05).TACtreatmentresultedinconsistentlybetterEFSthanTCtreatment:theestimated5-yearEFSwas66.1%vs.29.8%(P=0.002).Moreover,theestimated5-yearOSwasalsoinfavorofTAC:88.4%vs.51.6%(P<0.001).Multivariableanalysisdemonstratedthatthetreatmentregimenwasanindependentprognosticfactor,andpatientstreatedwithTAChadasuperiorEFS[hazardratio(HR),0.48;95%confidenceinterval(95%CI),0.26–0.90;P=0.021]andOS(HR,0.20;95%CI,0.08–0.60;P=0.003).Conclusions:Theupdatedlong-termfollow-updatademonstratedasustainedbenefitinEFSandOSfromanthracycline-containingTACtreatment,indicatingthatanthracyclineisanessentialandeffectivedruginthisclinicaltrial.